Xenetic Biosciences
Develops DNase-based adjuncts for cancer therapy and armored CAR-T treatment.
Something off on this page? Send us feedback.
Profile
Develops DNase-based cancer-treatment adjuncts, including systemic DNase I and a DNase I-armored CAR-T approach. Its asset-light program relies on third parties, while all revenue comes from royalties on a legacy PolyXen sublicense.
Develops systemic DNase I and DNase I-armored CAR-T programs intended to clear neutrophil extracellular traps that may hinder cancer treatment. XBIO-015 targets pancreatic carcinoma and other solid tumors, while XBIO-020 is designed to deliver DNase I in the tumor microenvironment alongside CAR-T tumor-killing activity.
Operates through external specialists: candidate manufacturing, preclinical research, translational work and exploratory studies span United States partners and Israeli medical centers. Its only revenue is royalty income from a Takeda sublicense of legacy PolyXen patents, not drug sales.
Maintains no internal research facility and depends on contract manufacturers, contract research organizations, academic institutions, consultants, licensed rights from CLS Therapeutics and investigator-led study partners.
Company facts
Key statistics
Year to date +84.2% · Average volume (30d) 55.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | — | −$0.41 | — | — | $660.6K | — | −2.52% |
| Aug 6, 2026Q2 FY26 | — | −$0.41 | — | — | $660.6K | — | −3.72% |
| May 12, 2026Q1 FY26 | — | −$0.20 | — | — | $806.9K | — | +5.30% |
| Mar 12, 2026Q4 FY25 | −$0.52 | −$0.22 | +57.7% | $690.0K | $766.3K | +11.1% | +9.34% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $593.3K | $589.9K | $1.0M | $766.3K | $806.9K | $660.6K | |
| Gross profit | $593.3K | $589.9K | $1.0M | $766.3K | $806.9K | $660.6K | |
| Operating income | −$942.4K | −$724.4K | −$544.7K | −$623.0K | −$502.1K | −$971.7K | |
| Net income | −$903.1K | −$688.7K | −$509.9K | −$579.1K | −$456.4K | −$929.7K | |
| Diluted EPS | −$0.59 | −$0.45 | −$0.33 | −$0.25 | −$0.20 | −$0.41 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Operating margin | -158.9% | -122.8% | -53.0% | -81.3% | -62.2% | -147.1% |
Fiscal years (4-quarter sums)FY21 $1.2M · FY22 $1.7M · FY23 $2.5M · FY24 $2.5M · FY25 $3.0M
Revenue by product · Q1 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $6.5M · Total debt $0 · Total assets $7.0M · Shareholders' equity $6.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 2.29M · Float 2.21M · 96.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Renaissance Technologies LLC | 137.4K | 6.00% | 13G | May 14, 2026 |
| James F. Parslow · officer: Interim CEO and CFO | 100.0K | 4.36% | Form 4 | Apr 23, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Gilead Sciences
Approved CD19 CAR-T standard in large B-cell lymphoma.
- Bristol-Myers Squibb
Approved CD19 CAR-T benchmark with broad large B-cell lymphoma use.
- Novartis (ADR)
Approved CD19 CAR-T benchmark for large B-cell lymphoma.
- Allogene Therapeutics
Clinical allogeneic CD19 CAR-T challenger in large B-cell lymphoma.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Xenetic Biosciences | $3.98 | +0.51% | $9.1M | — | — | 2.8 | +12.0% |
| Gilead Sciences | $139.30 | −4.36% | $180.87B | — | 16.0 | 5.9 | +10.2% |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Novartis (ADR) | $153.81 | 0.00% | $292.35B | 23.2 | 16.4 | 5.3 | +0.9% |
| Allogene Therapeutics | $2.01 | −0.09% | $697.2M | — | — | 150.3 | — |
| Median | 18.9 | 16.0 | 5.6 | +5.7% |